Addex Announces Plan to Implement ADS Ratio Change

Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023

Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF 2.7 million from Indivior in Extended Substance Use Disorder Research Collaboration

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Addex Increases Issued Share Capital to Create Treasury Shares